Similares a Brensocatib, 1 Year Later: Who Benefits Most? | Mark Metersky, MD

20 vecinos (text_768) · 98 views · HCPLive · Estados Unidos


★	Brensocatib, 1 Year Later: Who Benefits Most? \| Mark Metersky, MD	HCPLive @hcplivenews	98	Estados Unidos
20	Rethinking GLP-1s: A Smarter Policy for Long-Term Metabolic Health	Metabolic Mind @metabolicmind	—	Estados Unidos	83
5	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	84
11	Diabetes Dialogue: FDA Approves Afrezza Inhaled Insulin for Pediatric Patients	HCPLive @hcplivenews	683	Estados Unidos	84
19	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	83
1	One Year of Brensocatib: How Bronchiectasis Care Has Changed	HCPLive @hcplivenews	399	Estados Unidos	94
9	What #Allergists Should Know About Broncho-Vaxom for Respiratory Tract Infection	HCPLive @hcplivenews	348	Estados Unidos	84
14	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	84
15	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	84
8	Wednesday's Daily Dose: A new mRNA flu vaccine, robotic surgery milestone and lung cancer screening	WKYC Channel 3 @wkycchannel3	170	Estados Unidos	84
3	REACH Study: Broncho-Vaxom (OM-85) Cuts Recurrent Respiratory Tract Infections	HCPLive @hcplivenews	134	Estados Unidos	85
2	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	86
12	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	84
4	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	85
7	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	84
16	Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients	HCPLive @hcplivenews	53	Estados Unidos	83
10	Respiratory Disorder Drug Therapy \| Chapter 27 – Brenner & Stevens’ Pharmacology (6th)	Last Minute Lecture @lastminutelecture	52	Estados Unidos	84
17	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	83
6	How Startups Can Avoid FDA Delays \| Mark Swanson, QRx Partners \| MedTech World North America 2026	MedTech World @medtechworld	29	Malta	84
13	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	84
18	Predicting Post-BLVR Pneumothorax With Quantitative CT \| ATS 2026	HCPLive @hcplivenews	23	Estados Unidos	83